TABLE 3.

Percentages of patients alive with a functioning graft who were taking TAC, CSA, SRL, and MMF at 60, 120, and 180 months post‐transplant.

(i) Percentage taking TAC
Post‐tx month	Group A: TAC/SRL	Group B: TAC/MMF	Group C: CSA/SRL	p value a
60	88.6% (31/35)	90.6% (29/32)	25.6% (10/39)	0.78
120	73.7% (14/19)	90.9% (20/22)	36.7% (11/30)	0.14
180	69.2% (9/13)	93.3% (14/15)	35.7% (5/14)	0.10
(ii) Percentage taking CSA
Post‐tx month	Group A: TAC/SRL	Group B: TAC/MMF	Group C: CSA/SRL
60	0.0% (0/35)	0.0% (0/32)	46.2% (18/39)
120	0.0% (0/19)	0.0% (0/22)	36.7% (11/30)
180	0.0% (0/13)	0.0% (0/15)	42.9% (6/14)
Post‐tx month	Group A: TAC/SRL	Group B: TAC/MMF	Group C: CSA/SRL	p ‐Value b
60	57.1% (20/35)	12.5% (4/32)	48.7% (19/39)	0.47
120	57.9% (11/19)	9.1% (2/22)	56.7% (17/30)	0.93
180	53.8% (7/13)	6.7% (1/15)	35.7% (5/14)	0.34
(iv) Percentage taking MMF
Post‐tx month	Group A: TAC/SRL	Group B: TAC/MMF	Group C: CSA/SRL
60	37.1% (13/35)	90.6% (29/32)	71.8% (28/39)
120	52.6% (10/19)	100.0% (22/22)	70.0% (21/30)
180	61.5% (8/13)	100.0% (15/15)	71.4% (10/14)

Abbreviations: CSA, cyclosporine microemulsion; MMF, mycophenolate mofetil; SRL, sirolimus; TAC, tacrolimus; tx, transplant.

^a The p values listed in this column represent chi‐squared test results comparing the group A versus B percentages at 60, 120, and 180 months post‐transplant, respectively.

^b The p values listed in this column represent chi‐squared test results comparing the group A versus C percentages at 60, 120, and 180 months post‐transplant, respectively.